As of June 12, 2025, Regeneron Pharmaceuticals Inc (REGN) reports a Forward P/E of 14.26.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Regeneron Pharmaceuticals Inc's Forward P/E to Peers
To better understand Regeneron Pharmaceuticals Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Regeneron Pharmaceuticals Inc (REGN) | 14.26 |
| TG Therapeutics Inc (TGTX) | 43.46 |
| Alkermes Plc (ALKS) | 17.47 |
| Incyte Corp (INCY) | 11.63 |
| Halozyme Therapeutics Inc (HALO) | 10.20 |
| United Therapeutics Corp (UTHR) | 9.80 |
Compared to its competitors, Regeneron Pharmaceuticals Inc's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.